Immutep (ASX:IMM) will present new clinical results from its AIPAC-003 Phase 2 trial at next week’s San Antonio Breast Cancer Symposium, highlighting encouraging response rates and clear signs of immune activation in heavily pretreated metastatic breast cancer patients. …
Immutep unveils strong Phase 2 data ahead of San Antonio breast cancer symposium
December 2, 2025 Australian Biotech
Latest Video
New Stories
-
Queensland cardiac experts back a new plan to stop the second heart attack
September 18, 2026 - - Latest News -
We have one of Australia's answers to 'MFN' and people will die as a result
September 18, 2026 - - Latest News -
Is the fairest part of our medicines access system delivered overseas?
September 18, 2026 - - Latest News -
Mayne Pharma bets on an untapped corner of the menopause market
September 17, 2026 - - Latest News -
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News